These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9789565)

  • 1. The mechanism of ATP-dependent multidrug transport by P-glycoprotein.
    Shapiro AB; Ling V
    Acta Physiol Scand Suppl; 1998 Aug; 643():227-34. PubMed ID: 9789565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.
    Shapiro AB; Ling V
    Eur J Biochem; 1997 Nov; 250(1):130-7. PubMed ID: 9432000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein.
    Shapiro AB; Ling V
    Eur J Biochem; 1998 May; 254(1):181-8. PubMed ID: 9652412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
    Tang F; Ouyang H; Yang JZ; Borchardt RT
    J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.
    Shapiro AB; Fox K; Lam P; Ling V
    Eur J Biochem; 1999 Feb; 259(3):841-50. PubMed ID: 10092872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates.
    Clay AT; Sharom FJ
    Biochemistry; 2013 Jan; 52(2):343-54. PubMed ID: 23268645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein.
    Shapiro AB; Ling V
    Eur J Biochem; 1998 May; 254(1):189-93. PubMed ID: 9652413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state.
    Lu P; Liu R; Sharom FJ
    Eur J Biochem; 2001 Mar; 268(6):1687-97. PubMed ID: 11248688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer.
    Shapiro AB; Corder AB; Ling V
    Eur J Biochem; 1997 Nov; 250(1):115-21. PubMed ID: 9431998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site.
    Lugo MR; Sharom FJ
    Biochemistry; 2005 Jan; 44(2):643-55. PubMed ID: 15641790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein.
    Shapiro AB; Ling V
    Eur J Biochem; 1997 Nov; 250(1):122-9. PubMed ID: 9431999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.
    Eckford PD; Sharom FJ
    Biochem Cell Biol; 2006 Dec; 84(6):1022-33. PubMed ID: 17215888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
    Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
    Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism.
    Qu Q; Chu JW; Sharom FJ
    Biochemistry; 2003 Feb; 42(5):1345-53. PubMed ID: 12564938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
    Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
    Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
    Chen Y; Pant AC; Simon SM
    Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein.
    Sarver JG; Klis WA; Byers JP; Erhardt PW
    J Biomol Screen; 2002 Feb; 7(1):29-34. PubMed ID: 11897053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.